Home | Back to newsletter main page

Case Comprehensive Cancer Center Newsletter

Special Edition August 11, 2010


ANNOUNCEMENTS

Craig Thompson Named President of Memorial Sloan-Kettering Cancer Center

Case CCC External Advisory Board member Craig B. Thompson, MD, has been named the new President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center effective November 2, 2010. His appointment concludes a search that began in January 2010. He succeeds Harold Varmus, MD, who left Memorial Sloan-Kettering in July 2010 and is now director of the National Cancer Institute.

For more information on his appointment, please click here.

Markowitz Colon Cancer Research Mentioned in New York Times

A colon cancer test based on the research of Dr. Sanford Markowitz, Dr. Bert Vogelstein of Johns Hopkins University, and Dr. David A. Ahlquist of the Mayo Clinic, was featured in a recent "New York Times" article, DNA Test May Speed Colon Cancer Diagnosis. The test, which measures methylated DNA in stool samples, is being developed by Exact Sciences, a molecular diagnostics company focused on colorectal cancer.


CASE CCC SEED FUNDING

Request for Proposals: Cancer Stem Cell and Cancer Originating Cell Research Projects

The Case Comprehensive Cancer Center will provide seed money to foster collaborations and to promote and increase institution-wide capacity and competitiveness in cancer stem cell and cancer originating cell based research. Four awards of $50,000 will be made to investigators who intend to gather preliminary data to be used in seeking future independently funded programs and support. Case Comprehensive Cancer Center members with a faculty appointment at all levels (eligible to apply for independent nationally competitive research grants) are encouraged to apply. Proposals from both junior and senior investigators are encouraged. Postdoctoral fellows, graduate students and research associates are not eligible to apply for these pilot grants.

It is expected that these grants will represent new initiatives, not otherwise funded in new areas of cancer stem cell research. Use of animal models of human disease, primary cancer stem cells and cancer originating cells isolated from human cancers, development of novel cell lines such as iPS of human cancers, and methods development for the isolation of cancer stem cells and cancer originating cell based would be responsive. The NIH ARRA award mechanism will be the source of funds for 2 awards, with matching funds for the additional two awards. Investigators should identify the Cancer Center Scientific Program under which this pilot application is submitted and have a letter from the Program Leader acknowledging the programmatic alignment. Program Leaders can be found on the Cancer Center web site.

Deadline: September 10

Details are available on the cancer center website.


Produced by:
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
216-844-8317 phone
216-844-7832 fax
gillian.irwin@case.edu

HELP US HELP YOU!

If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!

Send items to gillian.irwin@case.edu.